Previous studies have demonstrated that elevated lymphatic vessel density in conjunction with increased VEGFC expression was indicative of metastasis and unfavorable prognosis in patients diagnosed with prostate cancer.205 Lysophosphatidic acid increased the expression of VEGFC and promoted lymphangiogenesis by upregulating calreticulin in prostate cancer cells.206 Relevant studies are currently ongoing to investigate the potential of targeted lymphangiogenesis therapy in managing lymph node metastasis and distant metastasis of prostate cancer. The gene discussed is VEGFC; the disease is prostate cancer.